Werewolf Therapeutics, Inc.
HOWL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $20 | $16 | $0 |
| % Growth | -90.5% | 21.6% | – | – |
| Cost of Goods Sold | $2 | $2 | $3 | $0 |
| Gross Profit | $0 | $18 | $14 | $0 |
| % Margin | 3.8% | 91.2% | 84.7% | – |
| R&D Expenses | $56 | $42 | $54 | $35 |
| G&A Expenses | $19 | $19 | $17 | $15 |
| SG&A Expenses | $19 | $19 | $22 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $4 | $0 |
| Other Operating Expenses | -$2 | -$2 | -$5 | $0 |
| Operating Expenses | $74 | $59 | $70 | $50 |
| Operating Income | -$74 | -$41 | -$56 | -$50 |
| % Margin | -3,904.2% | -203.1% | -341.8% | – |
| Other Income/Exp. Net | $3 | $3 | $2 | $0 |
| Pre-Tax Income | -$71 | -$37 | -$54 | -$50 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$71 | -$37 | -$54 | -$50 |
| % Margin | -3,740.8% | -187.4% | -328.1% | – |
| EPS | -1.63 | -1.05 | -1.86 | -10.94 |
| % Growth | -55.2% | 43.5% | 83% | – |
| EPS Diluted | -1.63 | -1.05 | -1.86 | -10.94 |
| Weighted Avg Shares Out | 43 | 36 | 29 | 18 |
| Weighted Avg Shares Out Dil | 44 | 36 | 29 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $2 | $0 |
| Interest Expense | $5 | $3 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $3 | $0 |
| EBITDA | -$64 | -$32 | -$51 | -$50 |
| % Margin | -3,397.6% | -162.8% | -312.8% | – |